Formulation of protein/peptide products with novel liposomes to
improve their pharmacokinetics, efficacy and stability.
Employees: 10
Overview
OMRI developed a method for the prolongation of protein half-life
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
and efficacy by formulation with proprietary liposomes. The
proteins bind non-covalently but with high affinity in a specific
mode with the external surface of liposomes without loosing their
activity. OMRI identified a consensus sequence for this
interaction and developed a screening method to test interaction
of any protein/peptide with the liposomes. Animal experiments
with several proteins indicate that the half-life and biological
efficacy of liposome-formulated proteins are significantly
prolonged over those of free proteins following intravenous
and/or subcutaneous injection.
Advantages:
* The protein/peptide is formulated with the liposomes simply by
hydrating the dry protein concentrate with the liposome solution
(therefore, there is no need to change the protein/peptide
production process).
* All the proteins/peptides are therapeutically available.
* Longer half-life, higher area under the curve, higher efficacy
and better stability of the formulated protein/peptide.
